KospicyKorean filings in English
Filings / Quratis Inc.

Single Sales / Supply Contract

Quratis Inc. · 단일판매ㆍ공급계약체결

8-KKOSDAQ · 348080 Filed 2026-11-20Korean original on DART

Full translation

Single Sales/Supply Contract

1. Details of sales/supply contractClinical drug product supply contract
2. Contract detailsConditional contractNot applicable
Confirmed contract amount2,489,157,000
Conditional contract amount-
Total contract amount (KRW)2,489,157,000
Most recent revenue (KRW)2,456,943,982
Ratio to revenue (%)101.31
3. CounterpartyAccess to Advanced Health (UK) Ltd
- Most recent revenue (KRW)-
- Main businessDevelopment and distribution of vaccine technology
- Relationship with the company-
- Similar contracts performed with the company in the last 3 yearsNot applicable
4. Sales/supply regionLocation designated by the counterparty
5. Contract periodStart date2026-11-19
End date2030-06-30
6. Key contract termsDown payment/advance paymentNone
Payment terms, etc.Payment is made when the counterparty accepts the deliverables for each milestone
7. Sales/supply methodIn-house productionApplicable
Outsourced productionNot applicable
Other-
8. Contract (order) date2026-11-19
9. Disclosure deferralDeferral period-
Reason for deferral-
10. Other matters to consider for investment decisions
- The contract amount in 2. Contract details above is the total contract amount of USD 1,870,000 converted at Hana Bank's first published base exchange rate on 2026-11-19 (KRW 1,331.10/USD). - The most recent revenue in 2. Contract details above is based on the separate financial statements for fiscal year 2025. - The counterparty above is a subsidiary of AAHI (Access to Advanced Health Institue) in the United States. It is a new entity established in London, UK in 2025 and has no financial statements available. - Payment terms, etc. under 6. Key contract terms above: . Milestone 1: Contract / technical feasibility (USD 621,000) . Milestone 2: Process development / GMP production (USD 257,400) . Milestone 3: Preliminary stability (USD 102,600) . Milestone 4: CMC documentation (USD 399,000) . Milestone 5: Stability (USD 490,000)
※ Related disclosures-